InnovAgevsMerck & Company

INNV and MRK stock compared: price, dividend, valuation and results, from SEC filings.

MRK

Merck & Company, Inc.

$143.37

Value $354B

-0.75%
MRK's page

InnovAge (INNV) has a market value of $1.3B and Merck & Company (MRK) $354B. Over the last year, with dividends, INNV moved +94.6% and MRK +58.8%. The P/E is 142.9 for INNV and 144.5 for MRK. Dividend yield: INNV none, MRK 2.37%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    INNV$1.3B

    MRK$354B

    MRK is 276 times INNV

  • Revenue, 12 months

    INNV$1.0B

    MRK$67.4B

    MRK is 66 times INNV

  • Net income, 12 months

    INNV$9.0M

    MRK$2.5B

    MRK is 273 times INNV

  • Operating margin

    INNV1.4%

    MRK–

  • ROIC

    INNV3.8%

    MRK3.9%

    0.1 points apart

  • P/E

    INNV142.9

    MRK144.5

    About the same

  • Dividend yield

    INNV0.0%

    MRK2.4%

    2.4 points apart

  • 5-year return

    INNV+5.1%

    MRK+98.6%

    93.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

INNV+5.2%

MRK+98.6%

10020020222023202420252026
Returns by period
PeriodINNVWith dividendsMRKWith dividends
1 year since November 14, 2025+94.6%Price +94.6%+58.8%Price +54.3%
3 years since November 17, 2023+64.7%+18.1% a yearPrice +64.7%+54.4%+15.6% a yearPrice +40.9%
5 years since November 16, 2021+5.1%+1.0% a yearPrice +5.1%+98.6%+14.7% a yearPrice +70.5%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

INNVInnovAgeMRKMerck & Company

Valuation

INNVMRK
Valuation
Price$9.42$143.37
Market value$1.3B$354B
Enterprise value (EV)$1.2B$399B
P/E142.9144.5
P/E, 5-year median–14.8
P/B5.07.9
EV/EBIT81.783.7
Free cash flow yield5.9%4.2%

Results and growth

INNVMRK
Results and growth
Revenue, 12 months$1.0B$67.4B
Net income, 12 months$9.0M$2.5B
Free cash flow, 12 months$76M$14.7B
Earnings per share, 12 months$0.06$0.98
Revenue growth, year on year15.9%1.3%
Revenue growth a year, past+9.2%over 5 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

INNVMRK
Margins and returns on capital
Gross margin23.6%71.8%
Operating margin1.4%–
Net margin0.9%3.6%
ROIC3.8%3.9%
ROE3.7%5.2%

Balance sheet

INNVMRK
Balance sheet
Cash$163M$9.7B
Total debt$84M$53.8B
Net debt / EBITDA-2.95.7
Interest cover–2.4×

Dividends and buybacks

INNVMRK
Dividends and buybacks
Dividend yield–2.4%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.4%
Shareholder yield–3.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: INNV or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, InnovAge or Merck & Company?

By market value, Merck & Company ($354B) is about 275.8 times InnovAge ($1.3B), at today's prices.

How did INNV and MRK stock do over the last 5 years?

Since November 16, 2021, INNV's price moved +5.1% and MRK's +70.5%. With dividends: INNV +5.1% (+1.0% a year), MRK +98.6% (+14.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, INNV or MRK?

The dividend yield at today's price is none for InnovAge and 2.37% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

What is the P/E of INNV and MRK?

At today's price, the P/E is 142.9 for INNV and 144.5 for MRK. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, InnovAge or Merck & Company?

Over the last twelve months, the net margin was 0.9% for InnovAge and 3.6% for Merck & Company, and the operating margin 1.4% and –. Revenue was $1.0B and $67.4B.

Which is the better investment, InnovAge or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.